Article
Immunology
Georg Christian Lodde, Frederik Krefting, Jan-Malte Placke, Lea Schneider, Melanie Fiedler, Ulf Dittmer, Juergen Christian Becker, Stefanie Hoelsken, Dirk Schadendorf, Selma Ugurel, Wiebke Sondermann
Summary: This prospective single-center cohort study aimed to determine the rate of seroconversion after COVID-19 vaccination in patients under active systemic treatment for moderate to severe psoriasis. The results showed that 96.1% of patients undergoing systemic treatment for psoriasis achieved anti-SARS-CoV-2-S IgG seroconversion after COVID-19 vaccination, but impaired immune response was observed in patients receiving MTX and/or TNF-alpha inhibitors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Yukari Okubo, Ann Chuo Tang, Sachie Inoue, Hitoe Torisu-Itakura, Mamitaro Ohtsuki
Summary: The study found that patients and physicians using biologics have higher treatment goals compared to non-biologics users, and biologic users also reported higher treatment satisfaction. Setting appropriate treatment goals that are shared between patients and their physicians may lead to better treatment outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Pui-Ying Leong, Tsu-Man Chiu, James Cheng-Chung Wei, An-Ping Huo
Summary: This case report presents a rare occurrence of psoriasis combined with vitiligo in an Asian boy under the age of 6, and demonstrates that symptom improvement can be achieved with the use of methotrexate, indicating shared immune pathways between the two diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Dan Wu, Xin Shou, Yunru Yu, Xiaocheng Wang, Guopu Chen, Yuanjin Zhao, Lingyun Sun
Summary: A novel photo-thermally dissolvable hyaluronic acid microneedle patch with biologics encapsulation has been developed for the treatment of psoriasis. The microneedles possess suitable mechanical strength and biocompatibility, allowing for minimal immune response upon skin puncture. The rapid melting and release of encapsulated IL-17 mAbs under near-infrared light irradiation provide an effective anti-inflammatory effect around psoriasis lesions. This multifunctional microneedle patch effectively reduces psoriasis-like skin inflammation in an animal model and offers a safer and more effective strategy for psoriasis treatment and other chronic inflammatory autoimmune diseases.
ADVANCED FUNCTIONAL MATERIALS
(2022)
Article
Dermatology
Emanuele Trovato, Corinne Orsini, Filomena Russo, Giulio Cortonesi, Pietro Rubegni
Summary: Erythodermic psoriasis is a rare subset of psoriasis considered a dermatologic emergency, with limited clinical evidence and unknown pathogenesis. In addition to conventional therapies, studies suggest that biologics may be a new treatment option.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Selma Atalay, Lara S. van der Schoot, Laura Vandermaesen, Lieke J. van Vugt, Mascha Eilander, Juul M. P. A. van den Reek, Elke M. G. J. de Jong
Summary: The study found that a tightly controlled dose reduction strategy for adalimumab, etanercept, and ustekinumab in patients with psoriasis can safely decrease drug dosages and maintain the use of lower doses.
ACTA DERMATO-VENEREOLOGICA
(2021)
Review
Biochemistry & Molecular Biology
Hye One Kim, Seok Young Kang, Jin Cheol Kim, Chun Wook Park, Bo Young Chung
Summary: Psoriasis is a chronic inflammatory systemic disease that primarily affects the skin, with one-third of cases starting in childhood. Pediatric psoriasis has unique clinical characteristics, but treatment usually involves methods similar to adults. Research on pediatric psoriasis is lacking, and targeted therapies using newly developed biologics are increasingly being applied.
Article
Immunology
Weize Gao, Zhan Wang, Wenshuai Li, Yongxin Li, Mingjun Liu
Summary: This review systematically demonstrates the research progress of psoriasis-related biomarkers and elaborates their related mechanisms in the pathological development of psoriasis and psoriatic arthritis. In addition, we summarize the development of biologic therapies for psoriasis and psoriatic arthritis in order to drive the broader discussion of psoriasis as an autoimmune-mediated inflammatory skin disease.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Geriatrics & Gerontology
E. L. M. ter Haar, S. E. Thomas, J. M. P. A. van den Reek, M. E. Otero, M. D. Njoo, P. M. Ossenkoppele, E. N. Kop, S. R. P. Dodemont, J. E. M. Korver, A. L. A. Kuijpers, R. J. Lindhout, R. A. Tupker, J. M. Mommers, M. A. M. Berends, M. I. A. Koetsier, M. S. de Bruin-Weller, M. B. Visch, W. P. Arnold, P. P. M. van Lumig, M. M. Kleinpenning, S. F. K. Lubeek, E. M. G. J. de Jong
Summary: This real-world observational study compares the drug survival and safety of biologics in older patients and younger patients with psoriasis. The study finds that biologics treatment in older patients is well-tolerated and effective, with comparable overall drug survival and adverse event-related drug survival to younger patients. However, older patients have a lower drug survival due to ineffectiveness, but no clear difference in Psoriasis Area and Severity Index (PASI) scores is observed.
Review
Biotechnology & Applied Microbiology
Sindhuja Koppu, Rohan Singh, Kiranjit Kaur, Steven R. Feldman
Summary: Bimekizumab, a promising treatment for moderate-to-severe plaque psoriasis, has shown efficacy and tolerability in clinical trials.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Dermatology
Hsien-Yi Chiu, Ying-Ming Chiu, Nien-Feng Chang Liao, Ching-Chi Chi, Tsen-Fang Tsai, Chang-Yu Hsieh, Tsu-Yi Hsieh, Kuo-Lung Lai, Tsu-Man Chiu, Nan-Lin Wu, Rosaline Chung-yee Hui, Chaw-Ning Lee, Ting-Shun Wang, Po-Hua Chen, Chao-Chun Yang, Yu-Huei Huang
Summary: This study found that patients with psoriasis receiving biologics are at risk of HBV and HCV reactivations, especially those who are HBsAg and HBeAg positive and undergoing tumor necrosis factor-alpha-inhibitor therapy. Antiviral prophylaxis was effective in reducing the risk of HBV reactivation. No predictors were significantly associated with HCV reactivation.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Dermatology
C. Grodner, E. Sbidian, A. Weill, M. Mezzarobba
Summary: This study estimated the prevalence of psoriasis patients receiving treatment in France and found it to be 1.3%. The most common comorbidities associated with psoriasis patients were hypertension, dyslipidaemia, diabetes, and chronic obstructive pulmonary disease. The study highlighted the utility and reliability of using insurance databases for research purposes.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Allergy
Paolo Gisondi, Stefano Piaserico, Luigi Naldi, Paolo Dapavo, Andrea Conti, Piergiorgio Malagoli, Angelo Valerio Marzano, Federico Bardazzi, Massimo Gasperini, Simone Cazzaniga, Antonio Costanzo
Summary: The study found that there was no significant increase in hospitalization and death rates for COVID-19 in patients with chronic plaque psoriasis receiving biologic therapies compared to the general population. Therefore, discontinuation of biologic therapies is not advised to prevent COVID-19 in these patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Review
Dermatology
James Krueger, Lluis Puig, Diamant Thaci
Summary: Generalized pustular psoriasis (GPP) is a rare and severe skin disorder without approved specific therapies. Current treatment options are based on limited evidence and recent advances have identified potential targets for targeted therapy based on improved understanding of the disease mechanisms and gene mutations associated with GPP.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Dermatology
Clinton W. Enos, Vanessa L. Ramos, Robert R. McLean, Tin-Chi Lin, Nicole Foster, Blessing Dube, Abby S. Van Voorhees
Summary: The study found that obesity and a history of diabetes reduce the likelihood of patients responding to biologic treatment, especially in achieving certain levels of disease improvement. Obesity is associated with lower response to TNFi and IL-17i biologics, while diabetes is associated with poorer outcomes when using IL-17i therapy, independent of obesity.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Linda Davidson, Juul M. P. A. Van den Reek, Florence Van Hunsel, Elke M. G. J. De Jong, Bart Jan Kullberg
Summary: This study analyzed spontaneous safety reports to identify associations between different biologics and bacterial skin or herpesvirus infections. The results showed that ustekinumab was strongly associated with bacterial skin infections, while infliximab showed the strongest association with herpes simplex and Epstein-Barr virus infections. All biologics were positively associated with bacterial skin infections, herpes simplex, and herpes zoster.
ACTA DERMATO-VENEREOLOGICA
(2022)
Letter
Dermatology
M. E. C. van Winden, F. M. Klosters, M. Hamaker, M. G. Olde Rikkert, P. C. M. van de Kerkhof, E. M. G. J. de Jong, S. F. K. Lubeek
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Marloes. E. Van Muijen, Sarah E. Thomas, Hans M. M. Groenewoud, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Sharon R. P. Dodemont, Else N. Kop, Maartje A. M. Berends, Marjolein I. A. Koetsier, Johannes M. Mommers, John E. M. Korver, Ron A. Tupker, Marjolein S. De Bruin-Weller, Lizelotte J. M. T. Weppner-Parren, Bas Peters, Marloes M. Kleinpenning, Astrid L. A. Kuijpers, W. Peter Arnold, Paula P. M. Van Lumig, Juul M. P. A. Van den Reek, Elke M. G. J. De Jong
Summary: Real-world evidence comparing the effectiveness of different biologic therapies for psoriasis shows that adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab are more effective in reducing PASI scores and achieving PASI90 than etanercept. Ixekizumab and guselkumab have higher probabilities of achieving PASI90 than other treatments. The proportions of patients reaching PASI90/75 are lower in real-world studies compared to randomized controlled trials.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
Elke L. M. ter Haar, Marcia Tummers, Ewald M. Bronkhorst, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong, Satish F. K. Lubeek
Summary: There is sparse evidence-based guidance for psoriasis treatment in older adults, leading to potential undertreatment. A survey and interviews with dermatologists in the Netherlands revealed age-based treatment differences and some reluctance to prescribe systemic therapy in older adults. Comorbidity, comedication, and fear of adverse events were identified as the main reasons for these differences. The study highlights the need for more evidence-based guidance, education, and consultation time to improve treatment in the growing population of older adults with psoriasis.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
Elke L. M. Ter Haar, Eline E. Ten Bruin, Ewald M. Bronkhorst, Rinke J. Borgonjen, Marloes M. Kleinpenning, Else N. Kop, M. Birgitte Visch, Peter C. M. Van De Kerkhof, Elke M. G. J. De Jong, Satish F. K. Lubeek
Summary: This multicentre retrospective study examined the safety of systemic therapy in older adults with psoriasis and analyzed predictors for adverse events. The study found that increasing age was associated with a higher incidence of adverse events, while comorbidity, polypharmacy, and treatment type were not related to adverse event occurrence. Causality assessment showed that serious adverse events were rare and manageable in clinical practice, indicating a reassuring safety profile for systemic antipsoriatic therapy in this population.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe
Summary: The study aimed to estimate the prevalence of SARS-CoV-2 infection in psoriasis patients, compare infection rates among different treatment groups, and describe severe COVID-19 cases. The findings suggest that the risk of SARS-CoV-2 infection is not increased for psoriasis patients using biologics or non-biologic systemic therapy compared to other treatments.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Tamara W. Van Hal, Michelle L. M. Mulder, Mark H. Wenink, Frank H. J. Van Den Hoogen, Jake S. F. Maurits, Marcel C. Pasch, Juul M. P. A. Van Den Reek, Elke M. G. J. De Jong
Summary: In this study, researchers used data from the DAPPER study to identify predictive variables for concomitant psoriatic arthritis and created a referral tool based on these variables, with an area under the curve of 0.82. This referral tool could assist dermatologists in identifying psoriasis patients with concomitant psoriatic arthritis.
ACTA DERMATO-VENEREOLOGICA
(2023)
Article
Dermatology
L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong
Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Letter
Dermatology
Inge M. G. J. Bronckers, Elke M. G. J. de Jong, Celia A. J. Michielsens, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Marieke M. B. Seyger
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn, Phyllis I. Spuls
Summary: This study compared the long-term effectiveness and safety of the combination of methotrexate and adalimumab with adalimumab monotherapy in patients with moderate to severe plaque type psoriasis. The results showed a trend towards longer drug survival in the combination therapy group, but no significant difference was found compared to the monotherapy group. Similar conclusions were drawn regarding the efficacy, safety, pharmacokinetics, and immunogenicity of the drugs. Overall, combination therapy may have a better effect in individual patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Editorial Material
Dermatology
Sarah E. Thomas, Juul M. P. A. Van den Reek, Marieke M. B. Seyger, Elke M. G. J. de Jong
Summary: In this study, the researchers aimed to synthesize the various definitions of super-responders in psoriasis literature and evaluate their impact on the composition of the super-responder group.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Dermatology
Sarah E. Thomas, Juul M. P. A. Van den Reek
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek
Summary: This study aimed to explore patients' perspectives towards dose reduction of biologics for psoriasis. Patients perceived benefits of dose reduction including minimizing medication use, lowering risks of adverse effects, and lowering healthcare costs. However, they also expressed concerns about the potential loss of disease control. Addressing patients' concerns, fulfilling information needs, providing the possibility of resuming standard dose, and involving patients in decision-making are important when considering biologic dose reduction.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)